Manufacturing Start Is Positive, but Reimbursement Request Is Far From Done
Read source articleWhat happened
Spectral AI has started manufacturing its first 30 DeepView AI systems, matching the BARDA-backed procurement plan disclosed in filings. The company also requested a $2,750 per-patient Medicare add-on payment, a concrete step toward hospital economics that remains a request rather than an approved rate. These developments align with management's post-clearance launch narrative but do not yet convert into product revenue or named commercial placements. The master report's WAIT rating and $1.35 attractive entry remain intact because cash burn, dilution risk, and lack of sales infrastructure still dominate the near-term outlook. Investors should treat this as incremental execution progress, not a thesis-changing event, and watch for SEC filing evidence of actual deployments and sales conversion by December 2026.
Implication
The start of manufacturing for up to 30 systems is a positive signal that BARDA-funded procurement is moving from contract to equipment build, but it does not mean any hospital has paid for or adopted the system. The $2,750 per-patient reimbursement add-on request is a constructive lobbying move, yet CMS decisions can take many quarters and may be denied, leaving hospitals without a clear payment path. With no product revenue, a thin cash position, and ongoing dilution risk, the stock remains a call on flawless execution over the next 6-12 months. Investors should not add at current prices; the WAIT rating implies waiting for either a pullback to around $1.35 or confirmation of first product revenue and disclosed placements. A break below the attractive entry on negative news would confirm the bear scenario, while a durable move above $2.40 on actual sales evidence would force a reassessment toward the bull case.
Thesis delta
The news does not alter the WAIT rating or the margin-of-safety assessment. Manufacturing the first units is an expected step within the BARDA program and the reimbursement request is still pending CMS action, so it adds only modest positive signal. The core thesis still requires first product revenue, disclosed placements, and cleaner financing before the risk/reward shifts.
Confidence
moderate